✓ Translated by DotMD AI Clinical Council Source: European journal of cancer (Oxford, England : 1990) • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #40680466 ↗

Phase III Randomized Trial: Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients - A post-hoc analysis of the PETACC 8 trial

Original Paper Title: “Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients - A post-hoc analysis of the PETACC 8 trial”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Among 2559 patients, median number of CM intake was 8 (range 0-25), with only 22 patients (0.9 %) without any CM intake. Anticoagulation treatment was the only CM category being significantly and independently associated with a shorter disease-free survival (DFS) (HR 1.29, 95 %CI 1.06-1.56, p = 0.010) as well as overall survival (OS) (HR.
  • Study Design & Sample: Phase III Randomized Trial published in European journal of cancer (Oxford, England : 1990) (Multi-cohort synthesis).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in European journal of cancer (Oxford, England : 1990) (2025), this phase iii randomized trial evaluating human clinical outcomes investigated: Only few information is available about the impact of concomitant medication (CM) and comorbidities on the outcome of cancer patients and the tolerability of chemotherapy. Key clinical takeaway: Among 2559 patients, median number of CM intake was 8 (range 0-25), with only 22 patients (0.9 %) without any CM intake. Anticoagulation treatment was the only CM category being significantly and independently associated with a shorter disease-free survival (DFS) (HR 1.29, 95 %CI 1.06-1.56, p = 0.010) as well as overall...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (European journal of cancer (Oxford, England : 1990), 2025-09-09; Phase III Randomized Trial; Rigor 82/100): Among 2559 patients, median number of CM intake was 8 (range 0-25), with only 22 patients (0.9 %) without any CM intake. Anticoagulation treatment was the only CM category being significantly and independently associated with a shorter disease-free survival (DFS) (HR 1.29, 95 %CI 1.06-1.56, p = 0.010) as well as overall survival (OS) (HR.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: oxaliplatin → Rx: cetuximab → Rx: fluorouracil → Rx: tolak-fluorouracil → Condition: cancer → Condition: cancer-immunotherapy →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 40680466: Phase III Randomized Trial: Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients - A post-hoc analysis of the PETACC 8 trial

3 of 3 Free Questions Remaining